Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy

Published:2024-05-14 Issue:7 Volume:20 Page:745-763
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Dreyzin Alexandra¹²,Rankin Alexander W.¹,Luciani Katia³,Gavrilova Tatyana⁴,Shah Nirali N.¹

Affiliation:

1. Pediatric Oncology Branch, Center of Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

2. Division of Pediatric Oncology, Children’s National Hospital, Washington DC, USA

3. School of Medicine, University of Limerick, Limerick, Ireland

4. Hematology/Oncology, National Cancer Institute, Bethesda, MD, USA

Funder

National Institutes of Health

National Cancer Institute

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2024.2349738

Reference213 articles.

1. From bench to bedside: the history and progress of CAR T cell therapy

2. Chimeric Antigen Receptor Therapy

3. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

4. Long-term outcomes following CAR T cell therapy: what we know so far

5. CAR-T State of the Art and Future Challenges, A Regulatory Perspective

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP